Japan Contract Development and Manufacturing Organization (CDMO) Market Analysis Report 2022: A $19.5 Billion Market by 2030 – Growing Demand for Biopharmaceutical Drugs Bolsters Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Japan Contract Development and Manufacturing Organization Market Size, Share & Trends Analysis Report by Product (API, Drug Product), by Workflow (Clinical, Commercial), by Application, and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering.

The Japan contract development and manufacturing organization market size is expected to reach USD 19.5 billion by 2030 and is anticipated to expand at a CAGR of 6.7% from 2022 to 2030

The main drivers of this market are rising investment by contract development and manufacturing organizations (CDMOs) for capacity expansion, a high geriatric population and growing disease burden in Japan, and low costs associated with outsourcing drug manufacturing and development services.

The COVID-19 pandemic boosted the demand for the CDMO market. Several CDMOs in Japan had tried to improve their capability by expanding their facilities even during the pandemic. For instance, in August 2020, Bushu Pharmaceuticals expanded its facility in the Misato plant in Japan to be dedicated to the storage of temperature-controlled sterile drugs and biologics.

Similarly, in July 2020, CMIC Group established a new facility in Japan dedicated to processing development and GMP manufacturing of antibody drugs. Such initiatives by CDMOs in the country are expected to have a positive impact on the market.

The market players are continuously engaging in major strategic initiatives like expanding their facilities, collaborating, partnerships, new service launches, and mergers & acquisitions. For instance, in May 2020, Catalent, a market leader in clinical supply services, announced plans to buy a clinical packaging facility from Teva-Takeda Pharmaceuticals, Nagoya Aichi, Japan.

By making this purchase, a new clinical GMP production and distribution hub will be created to assist clinical research. Furthermore, in July 2022, Catalent announced that it would be constructing a high-speed blister packaging line in Shiga, Japan. This will be in addition to its automated fill-and-finish production facility.

Japan Contract Development And Manufacturing Organization Market Report Highlights

• The API product segment accounted for the largest revenue share of 80.9% in 2021. The product segment is divided into API and drug product
• Based on application, the commercial segment dominated the market in 2021. This is due to the rising demand for generic drugs, and the high burden of chronic diseases are some factors contributing to the growth
• The oncology segment is anticipated to register the fastest CAGR of 7.2% during the forecast period, due to the growing number of cancer cases in the country which is improving the demand for new cancer therapeutics
• In November 2020, WuXi AppTec expanded its services offered by Cell & Gene Therapy Platform. The platform is now capable of developing, manufacturing, and introducing cell and gene therapies faster and with greater predictability

Market Dynamics

Market Driver Analysis

• Growing demand for Biopharmaceutical drugs in Japan
• High geriatric population and growing disease burden in Japan
• Low cost associated with Outsourcing Drug Manufacturing and Development services

Market Restraint Analysis

• Limited outsourcing opted for by big pharma companies
• Quality Issues While Outsourcing

Japan CDMO Market Analysis Tools

• Porter’s Five Forces Analysis
• PESTEL Analysis

Major Deals & Strategic Alliances Analysis

• Expansions
• Partnerships and Collaboration
• Mergers and Acquisitions
• Service and Product Launch
• Joint Venture

COVID-19 Impact

Competitive Landscape

• Cordenpharma International
• Wuxi Apptec
• Cambrex Corporation
• Recipharm Ab
• Lonza
• Catalent, Inc.
• Laboratory Corporation of America Holdings
• Thermo Fisher Scientific, Inc
• Samsung Biologics
• Fujifilm Corporation (Fujifilm Diosynth Biotechnologies U.S.A.)
• Sumitomo Chemical Company, Limited
• Cmic Holdings Co. Ltd
• Bushu Pharmaceuticals Ltd.
• Nipro

For more information about this report visit https://www.researchandmarkets.com/r/xjm1zu

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900